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ORIGINAL RESEARCH
Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in 
colorectal cancer liver metastases and matched primary tumors is associated with a 
poorer prognosis
Sandrine Nugterena, Jeroen A.C.M. Goosb, Pien M. Delis-van Diemenc, Ytje Simons-Oosterhuisa, Dicky J. Lindenbergh- 
Kortlevea, Daniëlle H. van Haaftena, Joyce Sanders c, Gerrit A. Meijer c, Remond J.A. Fijnemanc, 
and Janneke N. Samsoma
aLaboratory of Pediatrics, Division Gastroenterology and Nutrition, Erasmus University Medical Center, Rotterdam, The Netherlands; bDepartments of 
Clinical Neuroscience, Radiopharmacy, and Oncology & Pathology, Karolinska Institute, Stockholm, Sweden; cDepartment of Pathology, The 
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ABSTRACT
Secretory leukocyte protease inhibitor (SLPI), a pleiotropic protein expressed by healthy intestinal epithe-
lial cells, functions as an inhibitor of NF-κB and neutrophil proteases and exerts antimicrobial activity. We 
previously showed SLPI suppresses intestinal epithelial chemokine production in response to microbial 
contact. Increased SLPI expression was recently detected in various types of carcinoma. In addition, 
accumulating evidence indicates SLPI expression is favorable for tumor cells. In view of these findings 
and the abundance of SLPI in the colonic epithelium, we hypothesized SLPI promotes colorectal cancer 
(CRC) growth and metastasis. Here, we aimed to establish whether SLPI expression in CRC is related to 
clinical outcome. Using a cohort of 507 patients with CRC who underwent resection of liver metastases, 
we show that high SLPI protein expression in both liver metastases and primary CRC is associated with 
significantly shorter overall survival after resection of liver metastases. The prognostic value of SLPI in CRC 
patients with liver metastases implies a role for SLPI in the formation of metastasis of human CRC. Based 
on the immune regulatory functions of SLPI, we anticipate that expression of SLPI provides tumors with 
a mechanism to evade infiltration by immune cells.
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Introduction
The pleiotropic protein secretory leukocyte protease inhibitor 
(SLPI) is constitutively expressed and secreted by human 
epithelial cells.1,2 SLPI exerts diverse functions, including the 
ability to act as a potent NF-κB inhibitor3 and inhibit proteases 
such as neutrophil elastase4 and also exhibits broad antimicro-
bial properties.5–7 We previously showed that repetitive micro-
bial contact-induced expression of SLPI in intestinal epithelial 
cells and that SLPI suppressed chemokine production in 
response to microbial signals by inhibiting NF-κB activation.8 
Thus, SLPI prevents excessive inflammation during intestinal 
homeostasis.
Tumors frequently modulate the expression of immunomo-
dulatory proteins to evade anti-tumor immune responses. Most 
investigations of immune invasion in CRC have focused on the 
interactions between tumor cells and T cells or natural killer 
(NK) cells.9,10 However, innate immune proteins can also reg-
ulate the anti-tumor immune response.11 Increased SLPI protein 
expression is observed in several types of cancer, including 
colorectal cancer (CRC), 12 gastric cancer, 13 non-small cell 
lung cancer14 and ovarian cancer.15 While the roles of SLPI in 
tumor formation and progression have not been fully elucidated, 
multiple human and mouse studies indicate a role for SLPI in the 
formation of metastases. In particular, in a mouse model of 
polyclonal breast cancer, clones expressing SLPI entered the 
vasculature and formed metastases more efficiently than clones 
that did not express SLPI.16 In addition, SLPI promoted sponta-
neous lung metastasis in an orthotopic mouse model of breast 
cancer .17 Moreover, high tumor SLPI mRNA expression was 
associated with shorter overall survival in patients with triple- 
negative breast cancer17 and expression of SLPI was associated 
with poorer five-year overall survival in gastric cancer.13 
However, some studies have not reported a tumor-promoting 
role for SLPI. For example, overexpression of SLPI in lung 
carcinoma cells reduced the number of liver metastases in 
a mouse model.18 This protective effect was associated with 
suppressed production of TNF-α and E-selectin in the liver, 
suggesting that formation of liver metastases in this model 
requires a proinflammatory environment.18 Thus, the precise 
role of SLPI in cancer has not yet been fully elucidated.
The role of SLPI in human CRC has not been investigated. 
However, SLPI was one of four secreted proteins upregulated 
in the conditioned medium of a highly metastatic human 
colorectal cancer cell line compared to the poorly metastatic 
parental cell line.17 In addition, overexpression of SLPI 
enhanced tumor growth in murine colon cancer cells.19 In 
view of the immunoregulatory functions of SLPI in the 
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intestine and its potential tumor-promoting role, we hypothe-
sized that SLPI promotes tumor growth and metastasis in CRC. 
In this study, we aimed to establish whether expression of SLPI 
in human CRC metastases is associated with patient survival.
The liver is the most common site of metastasis in CRC; 
25–30% of patients with CRC develop colorectal cancer liver 
metastases (CRCLM).20–22 Approximately 25% of patients with 
CRCLM are eligible for surgical resection of the affected part of 
the liver, which is currently the only treatment with curative 
intent for CRC patients with liver metastases.23,24 However, 
survival outcomes after resection of CRCLM are highly variable, 
even among patients with similar clinical and pathology-based 
risk scores.25 A better understanding of tumor biology may help 
to predict survival for patients with CRCLM. Using a series of 
507 patients with CRC who underwent resection of liver metas-
tases, we show that SLPI protein expression in CRCLM and the 
matched primary tumors is associated with shorter overall 
survival.
Materials and methods
Patient cohort and tissue microarray (TMA) generation
Histologically confirmed, formaldehyde-fixed paraffin- 
embedded (FFPE) CRCLM tissue samples and, when available, 
samples of the corresponding primary tumor were collected 
from 507 patients who underwent resection of CRCLM between 
1990 and 2010 in seven Dutch hospitals (the DeCoDe PET 
group), as described previously.26 A previous power calculation 
indicated a sample size of 361 patients was required for a similar 
analysis.26 We assumed similar proportions of patients would 
exhibit low and high SLPI expression (50:50); therefore, we 
assumed that the sample size of this cohort (n = 507) would be 
sufficient. Patients with more than one primary tumor were 
excluded from this study. Tissue microarrays (TMAs) were 
generated from the original FFPE tissue blocks, according to 
previously described protocols.27 From every paraffin block, 
three tissue core biopsies of 0.6 millimeter in diameter were 
punched from morphologically representative areas and trans-
ferred into recipient TMA paraffin blocks. Four-micrometer 
TMA sections were cut and subsequently mounted onto glass 
slides. Collection, storage and use of the tissue samples and 
clinical data were conducted in compliance with the Dutch 
code of conduct for responsible use of human tissue for medical 
research.28
SLPI immunohistochemistry
TMA sections were deparaffinized in xylene and rehydrated in 
alcohol, incubated in 3% H2O2 in PBS for 20 min to quench 
endogenous peroxidase activity, and antigen retrieval was per-
formed by microwave treatment in citrate buffer (10 mM, pH 
6.0). Sections were blocked for one hour at room temperature in 
Tris buffer (10 mM, pH 8.0) containing 5 mM EDTA (pH 8.0), 
0.15 M NaCl, 0.25% gelatin, 0.05% Tween-20 and 10% normal 
human serum (AB serum; Sanquin, Amsterdam, The 
Netherlands) plus 10% normal horse serum (Biowest, Nuaillé, 
France) or 10% normal rabbit serum (Jackson ImmunoResearch, 
West Grove, PA, USA) matching the species in which the 
secondary antibody was raised. Subsequently, the sections were 
stained with either a monoclonal anti-human-SLPI antibody 
(4 μg/mL, mouse IgG1, HM2037, clone 31; HycultBiotech, 
Uden, The Netherlands) or polyclonal anti-human-SLPI anti-
body (1 μg/mL, goat IgG, BAF1274; R&D Systems/Bio-Techne, 
Minneapolis, MN, USA) in PBS overnight at 4°C. 
Immunoreactive sites were detected by incubation with 
a biotinylated horse-anti-mouse antibody (1:500, Vector 
Laboratories, Burlingame, CA, USA) or biotinylated rabbit-anti- 
goat antibody (1:500, Vector Laboratories) for 1 hour at room 
temperature. Biotinylated antibodies were detected using 
a complex of avidin and biotin (Vectastain ABC Elite Kit, 
Vector Laboratories) and 3,3ʹ-diaminobenzidine tetrahy-
drochloride (Sigma-Aldrich, Zwijndrecht, The Netherlands). 
Sections were counterstained with hematoxylin (Vector 
Laboratories) and subsequently dehydrated and immersed in 
xylene.
Scoring of SLPI expression
Images of stained sections were digitally captured using an 
Aperio AT2 scanner (Leica Microsystems B.V., Amsterdam, 
The Netherlands) equipped with a 20×/0.75 objective 
(UPlanSAPO; Olympus, Leiderdorp, The Netherlands). The 
intensity of SLPI protein expression in the cytoplasm of neo-
plastic epithelial cells was manually scored in a semi-quantitative 
manner as ‘negative’, ‘weak’, ‘moderate’ or ‘strong’ using the 
online platform Slide Score (www.slidescore.com). The scoring 
strategy was designed in consultation with a pathologist and 
based on the range of SLPI staining intensity observed in 
tumor cells; all sections were scored by the same investigator. 
In order to assess the reproducibility of the scoring, a second 
pathologist independently scored > 20% of the cores stained with 
the monoclonal antibody and > 20% of the cores stained with the 
polyclonal antibody, based on images of the scoring categories 
shown in Figure 1(a+b) and Figure 3(a+b). Both observers were 
blinded to the clinicopathological information at time of assess-
ment. The linear weighted kappa values were for 0.62 for the 
monoclonal antibody and 0.63 for the polyclonal antibody, indi-
cating fair to good interobserver agreement. The scoring method 
was agreed on by both observers and discrepancies were dis-
cussed by the observers.
Statistical analysis
For each tissue type (CRCLM or primary tumor) and anti-SLPI 
antibody, the maximum score from the one to three TMA cores 
stained for each patient was used for analysis. Patients for whom 
none of the three cores were evaluable were excluded from the 
respective analyses (Supplementary Figure 1). Overall survival 
was defined as the time after resection of CRCLM until death in 
months, with a maximum follow-up period of 60 months. 
Patients who died within 2 months of CRCLM resection were 
excluded from the analysis, to avoid bias related to death due to 
surgical complications (Supplementary Figure 1). Patients with 
missing survival status or follow-up data were also excluded 
from the analysis (Supplementary Figure 1).
The prognostic value of SLPI protein expression in the liver 
metastases and primary tumors was evaluated separately by 500- 
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fold cross-validation.26 In short, in each of the 500 cycles, the 
study population was randomly divided into equally sized train-
ing and validation sets. The optimal cutoff for dichotomizing the 
training set was calculated in every cycle using receiver operating 
characteristic (ROC) curve analysis for 3-year overall survival. 
This cutoff was subsequently applied to the validation set to 
calculate a cross-validated hazard rate ratio (HRR) for 3-year 
overall survival in univariable Cox regression analysis. In addi-
tion, a corrected HRR was calculated in each validation cycle by 
multivariable Cox regression analysis, which included the follow-
ing established clinical prognostic factors: number of CRCLM > 
1, primary tumor-to-CRCLM interval < 12 months, lymph node 
positivity at time of CRC diagnosis, and maximal CRCLM dia-
meter > 5.0 cm.29 In both the univariable and multivariable 
analysis, the average HRR (HRRav) of the 500 HRRs was used 
and the P-value was calculated based on the percentage of HRR < 
1 over the 500 cycles. The relation between SLPI expression and 
overall survival was visualized by Kaplan Meier curves both 
before and after dichotomization. Dichotomization for each anti-
body was performed using the cutoff that was most frequently 
selected during the automated 500-fold cross-validation proce-
dure. Patients were classified as ‘SLPI-low’ or ‘SLPI-high’ based 
on the cross-validated cutoffs for each antibody. The log-rank 
test was used to determine whether overall survival varied sig-
nificantly between the two groups. In addition, the time points at 
which 50% of the patients had died (median overall survival) and 
95% confidence intervals were calculated for both groups. The 
clinicopathological features of the SLPI-high and SLPI-low 
groups were compared using Pearson’s Chi-squared test for 
categorical variables and the Kruskal–Wallis rank sum test for 
non-normally distributed continuous variables. The relationship 
between SLPI detected using the monoclonal antibody and SLPI 
detected using the polyclonal antibody was examined using 
Fisher’s exact test (two-sided). The relationship between SLPI 
expression in liver metastases and the corresponding primary 
tumors was also tested using Fisher’s exact test (two-sided). All 
statistical analyses and visualization were performed using 
R version 3.5.1.30 The ‘survival’,31,32 ‘survminer’,33 ‘pROC’34 
and ‘survivalROC’35 packages were employed for survival analy-
sis and cross-validation. The data in this study is reported in 
compliance with the REMARK recommendations for reporting 
tumor marker prognostic studies.36
Results
SLPI is expressed in a subset of CRCLM
We assessed SLPI protein expression in CRCLM tissue samples 
from a Dutch cohort of 507 patients to establish the prognostic 
value of SLPI in CRCLM. The characteristics of this study 
Figure 1. SLPI is expressed in a subset of CRCLM. Examples of TMA cores of CRCLM stained for SLPI using the monoclonal antibody (a) or polyclonal antibody (b); SLPI 
staining intensity in tumor cells was scored. The frequencies and percentages of CRCLM scored as ‘negative’, ‘weak’, ‘moderate’ or ‘strong’ after staining with the 
monoclonal SLPI antibody (c) or polyclonal SLPI antibody (d) are shown; only the maximal score for each patient was included.
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population have been described previously.26 To robustly 
assess the prognostic value of SLPI, we detected SLPI protein 
expression by immunohistochemistry using two different anti-
bodies: a monoclonal antibody raised against human SLPI 
purified from sputum and a polyclonal antibody raised against 
Escherichia coli-derived recombinant human SLPI. CRCLM 
tissue samples stained with the SLPI monoclonal antibody 
from 386 patients were available for analysis and CRCLM 
samples stained with the SLPI polyclonal antibody from 372 
patients were available for analysis (Supplementary Figure 1a).
In whole tissue sections of primary CRC samples from 10 
patients, SLPI expression was homogeneous within each sec-
tion, but varied between tumors from different patients (data 
not shown). SLPI expression was mainly observed in the cyto-
plasm on the luminal side of the tumor cells (Figure 1(a+b)). 
We detected expression of SLPI in CRCLM in 45% of patients 
using the monoclonal antibody and in CRCLM in 72% of 
patients using the polyclonal antibody (Figure 1(c+d)). 
Overall, SLPI protein expression was detected in the CRCLM 
samples of a substantial subgroup of patients.
Expression of SLPI in CRCLM is associated with shorter 
overall survival
In order to assess the prognostic value of SLPI expression in 
CRCLM, we determined the optimal cutoffs for dichotomiza-
tion of the cohort using 500-fold cross-validation.
For CRCLM stained with the SLPI monoclonal antibody, 
the optimal cutoff in all 500 cross-validation cycles was nega-
tive vs. weak/moderate/strong SLPI expression (data not 
shown). The patients were classified as ‘SLPI-low’ or ‘SLPI- 
high’ based on this cross-validated cutoff. Using this cutoff, 
high SLPI expression in CRCLM was associated with signifi-
cantly shorter overall survival compared to low SLPI expres-
sion, with an average hazard rate ratio (HRRav) of 1.43 (P = .02; 
Supplementary Figure 2(a)). Furthermore, patients with high 
SLPI expression in CRCLM had significantly shorter overall 
survival after CRCLM resection compared to patients with low 
SLPI expression (log-rank test: P = .04; Figure 2(a+b)). The 
median overall survival time for patients with high SLPI 
expression was 44 months (95% confidence interval: 
38–60 months) compared to over 60 months (lower limit of 
the 95% confidence interval: 52 months) for patients with low 
SLPI expression in CRCLM (Figure 2(b)).
Using the polyclonal antibody, the optimal dichotomization 
cutoff was negative/weak (low) vs. moderate/strong (high) 
SLPI expression in all 500 cross-validation cycles (data not 
shown). Patients with high SLPI expression tended to have 
shorter overall survival compared to patients with low SLPI 
expression, though the HRRav of 1.33 was not statistically 
significant (P = .07; Supplementary Figure 2c). In the survival 
analysis, overall survival was not significantly different between 
the SLPI-high and SLPI-low groups for CRCLM stained using 
the polyclonal antibody (log-rank test: P = .10, Figure 2(c+d)). 
Median overall survival time was 41 months for the SLPI-high 
group (lower limit of the 95% confidence interval: 34 months, 
upper limit more than 60 months) and 58 months (lower limit 
of the 95% confidence interval: 48 months, upper limit more 
than 60 months) for the SLPI-low group (Figure 2(d)).
Patient age, gender, the location of the primary tumor, the 
grade of differentiation of the primary tumor, the size of the 
primary tumor, presence of lymph node metastases, presence of 
extrahepatic metastases, the interval between the primary tumor 
diagnosis and detection of liver metastases, the size of the liver 
metastases and the number of liver metastases were not signifi-
cantly different between patients with high or low SLPI expres-
sion in CRCLM tissues stained with either the SLPI monoclonal 
antibody or the polyclonal antibody (Supplementary Figure 3a 
+ b).
We also compared the SLPI expression scores for CRCLM 
from 357 patients stained with both the monoclonal and poly-
clonal antibody (Supplementary Figure 4a). There was 
a significant association between detection of high SLPI expres-
sion with the monoclonal antibody and detection of high SLPI 
expression with the polyclonal antibody (two-sided Fisher’s 
exact test: P < .01). For 74% of patients, both the monoclonal 
and polyclonal antibody resulted in the same classification, 
either ‘SLPI-low’ or ‘SLPI-high’ (Supplementary Figure 4a). 
SLPI expression was more frequently scored as ‘weak’ in 
CRCLM stained with the polyclonal antibody when no staining 
was detected using the monoclonal antibody than vice-versa, 
indicating the monoclonal antibody has a higher threshold of 
detection for SLPI. In conclusion, patients with high SLPI 
expression in CRCLM, as detected using the monoclonal anti-
body, have significantly shorter overall survival compared to 
patients with low SLPI expression in CRCLM.
SLPI expression in CRCLM has prognostic value 
independently of established clinical risk factors
Next, we determined whether expression of SLPI in CRCLM 
has prognostic value independently of established clinical risk 
factors. The following factors have been demonstrated to be 
associated with shorter overall survival after resection of liver 
metastases in patients with CRCLM: more than one CRCLM, 
a primary tumor-to-CRCLM interval less than 12 months, 
lymph node positivity at time of CRC diagnosis, a maximal 
CRCLM diameter > 5.0 cm and a serum carcinoembryonic 
antigen (CEA) level > 200 ng/mL .29 The prognostic value of 
these parameters was previously extensively assessed in the 
current cohort .26 The presence of more than one liver tumor 
was significantly associated with shorter overall survival. 
A primary tumor-to-CRCLM interval less than 12 months, 
lymph node positivity at the time of CRC diagnosis and 
a maximal CRCLM diameter > 5.0 cm were also associated 
with shorter overall survival (HRR > 1), though these trends 
were not statistically significant .26 Serum CEA > 200 ng/mL 
was not associated with overall survival in this cohort.26 
Therefore, we only included more than one CRCLM, 
a primary tumor-to-CRCLM interval less than 12 months, 
lymph node positivity at the time of CRC diagnosis, and 
a maximal CRCLM diameter > 5.0 cm in the multivariable 
Cox regression model.
Importantly, the prognostic value of SLPI expression 
detected using the monoclonal antibody was not con-
founded by these established clinical risk factors; high 
SLPI expression had a HRRav of 1.63 for overall survival 
in the multivariable model (P = .02; Supplementary Figure 
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2b). Detection of high SLPI expression using the polyclonal 
antibody was also associated with shorter overall survival 
compared to low SLPI expression in the multivariable 
model, though this trend was not statistically significant 
(HRRav 1.37; P = .10; Supplementary Figure 2d). Thus, 
detection of SLPI expression in CRCLM using the mono-
clonal antibody was associated with significantly shorter 
overall survival after surgical resection of liver metastases, 
independently of other known clinical risk factors.
SLPI is expressed in a subset of primary tumors from 
patients with CRCLM
It is currently unknown whether SLPI expression alters 
during the progression of tumors to metastasis. Therefore, 
we compared SLPI expression in CRCLM samples and 
primary CRC tissues; 168 paired CRCLM and the matched 
primary tumors from the same patients were available for 
this analysis (Supplementary Figure 1b). We observed 
similar patterns of SLPI expression in the primary tumor 
samples and CRCLM samples, with SLPI mainly expressed 
in the cytoplasm on the luminal side of the tumor cells 
(Figure 3(a+b)). SLPI expression was detected in the pri-
mary tumors of 60% of patients using the monoclonal 
antibody and 87% of patients using the polyclonal antibody 
(Figure 3(c+d)).
Using the monoclonal antibody to detect SLPI expres-
sion in primary CRC, the optimal cutoff for dichotomizing 
the patients was negative (low) vs. weak/moderate/strong 
(high) in 263 of the 500 cycles (data not shown). Based on 
this cutoff, the monoclonal antibody detected high SLPI 
expression in both the primary tumor and CRCLM in 
29% of patients and detected low SLPI expression in both 
the primary tumor and CRCLM in 26% of patients 
(Supplementary figure 5a). Expression of SLPI in the pri-
mary tumor was significantly associated with expression of 
SLPI in the corresponding liver metastases (two-sided 
Fisher’s exact test: P < .01). Using the monoclonal 
Figure 2. SLPI expression in CRCLM is associated with shorter overall survival. Kaplan-Meier overall survival curves after resection of liver metastases (in months) for the 
CRCLM study population. Overall survival was stratified by SLPI expression after staining with the monoclonal antibody (a + b) or polyclonal antibody (c + d). Curves 
without a cutoff (a + c) and with the cutoff calculated from the 500-fold cross-validation procedure (b + d) are shown. P-values were calculated using the log-rank test. 
The dotted lines represent the time point at which 50% of the group had died (median overall survival time). OS = overall survival.
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antibody, a higher proportion of primary tumors exhibited 
high SLPI expression than the matched CRCLM 
(Supplementary figure 5a).
Using the polyclonal antibody to detect SLPI expression in 
primary CRC, the optimal cutoff for dichotomization was 
negative/weak (low) vs. moderate/strong (high) in 480 out of 
500 cycles (data not shown). In 28% of patients, both the 
primary tumor and CRCLM expressed low levels of SLPI 
(Supplementary figure 5b). We detected high SLPI expression 
in both the primary tumor and CRCLM in 37% of patients. As 
observed for the monoclonal antibody, high SLPI expression in 
primary CRC was significantly associated with high SLPI 
expression in CRCLM using the polyclonal antibody (two- 
sided Fisher’s exact test: P = .02). Moreover, using the poly-
clonal antibody, more primary tumors exhibited high SLPI 
expression than the matched CRCLM (Supplementary fig-
ure 5b).
Overall, these results indicate SLPI expression in primary 
tumor samples is related to SLPI expression in CRCLM sam-
ples, which leads to the question of whether expression of SLPI 
in primary CRC is associated with the prognosis of patients 
with CRCLM.
SLPI expression in primary CRC is associated with shorter 
overall survival in patients with CRCLM
In order to establish whether primary tumor SLPI expression 
has prognostic value in patients with CRCLM undergoing 
surgical resection of their metastases, we examined the associa-
tion between SLPI expression in primary CRC and overall 
survival after CRCLM resection.
Detection of high SLPI expression in the primary tumor using 
the monoclonal antibody was associated with significantly 
shorter overall survival after CRCLM resection compared to 
low SLPI expression, with a HRRav of 1.80 (P = .02, 
Supplementary figure 6a). Furthermore, in the survival analysis, 
patients with high SLPI expression in the primary tumor had 
significantly shorter overall survival after CRCLM resection 
compared to patients with low SLPI expression in the primary 
tumor (log-rank test: P = .03; Figure 4(a+b)). The median overall 
survival time of patients with high SLPI expression in the pri-
mary tumor was 46 months after CRCLM resection (lower limit 
of 95% confidence interval: 32 months; upper limit, > 
60 months), compared to > 60 months (lower limit of 95% 
confidence interval: 52 months) for patients with low SLPI 
expression (Figure 4(b)).
Figure 3. SLPI is expressed in a subset of primary tumors from patients with CRCLM. Examples of TMA cores of primary CRC tumors stained for SLPI using the monoclonal 
antibody (a) or polyclonal antibody (b); SLPI staining intensity in tumor cells was scored. Frequencies and percentages of primary tumors scored as ‘negative’, ‘weak’, 
‘moderate’ or ‘strong’ after staining with the SLPI monoclonal antibody (c) or SLPI polyclonal antibody (d) are shown; only the maximal score for each patient was 
included.
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Detection of high SLPI expression in primary tumors using 
the polyclonal antibody was also associated with poorer overall 
survival, with an HRRav of 1.25; however, this effect was not 
statistically significant (P = .24; Supplementary figure 6 c). In 
addition, in the survival analysis there was no significant dif-
ference in overall survival between patients with low and high 
SLPI expression in the primary tumor detected using the poly-
clonal antibody (log-rank test: P = .44; Figure 4(c+d)). 
Moreover, the median overall survival time for patients with 
high SLPI expression was 52 months (lower limit of the 95% 
confidence interval: 41 months, upper limit > 60 months), 
compared to > 60 months (lower limit of the 95% confidence 
interval, > 60 months) in patients with low SLPI expression 
based on the polyclonal antibody (Figure 4(d)).
Expression of SLPI detected in primary CRC using either 
the monoclonal or polyclonal antibody was not related to 
patient age, the grade of differentiation of the primary tumor, 
primary tumor size, presence of lymph node metastases, pre-
sence of extrahepatic metastases, the interval between primary 
tumor diagnosis and detection of liver metastases, or the size or 
number of liver metastases (Supplementary Figure 3c + d). 
However, for primary tumors stained using the monoclonal 
antibody, the SLPI-high group more frequently had a primary 
tumor on the left side of the colon compared to the SLPI-low 
group (Pearson’s Chi-squared test: P = .04; Supplementary 
Figure 3c). However, we did not observe this association in 
analysis of primary tumors stained using the polyclonal anti-
body (Supplementary Figure 3d). In addition, in analysis of 
primary tumors stained with the polyclonal antibody, more 
patients in the SLPI-high group were female than in the SLPI- 
low group (Pearson’s Chi-squared test: P = .03; Supplementary 
Figure 3d), though we did not observe a similar association 
using the monoclonal antibody.
We were able to compare the SLPI scores for primary 
tumors stained using the monoclonal and polyclonal antibody 
for 157 patients (Supplementary Figure 4b). There was 
a significant association between detection of SLPI with the 
monoclonal antibody and the polyclonal antibody (two-sided 
Figure 4. SLPI expression in primary CRC is associated with shorter overall survival in patients with CRCLM. Kaplan-Meier overall survival curves after resection of liver 
metastases (in months) for the CRCLM study population. Overall survival was stratified by SLPI expression after staining with the monoclonal antibody (a + b) or 
polyclonal antibody (c + d). Curves without a cutoff (a + c) and with the cutoff calculated from the 500-fold cross-validation procedure (b + d) are shown. P-values were 
calculated using the log-rank test. The dotted lines represent the time point at which 50% of the group had died (median overall survival time). OS = overall survival.
ONCOIMMUNOLOGY 7
Fisher’s exact test, P < .01). Moreover, the monoclonal and 
polyclonal antibodies resulted in the same classification as 
either ‘SLPI-low’ or ‘SLPI-high’ in 72% of patients, 
(Supplementary Figure 4b). As observed for the CRCLM, we 
observed relatively lower SLPI staining scores using the mono-
clonal antibody than the polyclonal antibody in primary 
tumors.
In conclusion, detection of high SLPI expression in the 
primary tumors using the monoclonal antibody was associated 
with shorter overall survival after surgical resection of liver 
metastases in patients with CRCLM.
SLPI expression in primary CRC has prognostic value in 
patients with CRCLM independently of established clinical 
risk factors
Next, we investigated whether SLPI expression in primary CRC 
had independent prognostic value in patients with CRCLM by 
adjusting for previously established clinical risk factors. Using 
the multivariable model described earlier, detection of high 
SLPI expression in the primary tumor using the monoclonal 
antibody was associated with significantly shorter overall sur-
vival after resection of liver metastases compared to low SLPI 
expression (HRRav 1.86, P = .04; Supplementary figure 6b). For 
primary tumors stained with the polyclonal antibody, high 
SLPI expression was not significantly associated with shorter 
overall survival in the multivariable model (HRRav 1.26; 
P = .28; Supplementary figure 6d).
In conclusion, detection of high SLPI expression in primary 
tumor samples with the monoclonal antibody was significantly 
associated with shorter overall survival, independently of 
established clinical prognostic factors.
Discussion
SLPI is a small protein produced in large quantities by healthy 
epithelial cells throughout the body. The many functions of 
SLPI include modulation of the immune response via suppres-
sion of chemokine production.8 Recent studies indicated that 
SLPI drives metastasis in mammary carcinoma,16,17 but the 
role of SLPI in CRC tumor formation and progression is poorly 
characterized. In this analysis of a large cohort of patients with 
CRC who underwent resection of liver metastases, we demon-
strate high expression of SLPI in both the liver metastases and 
primary tumors is associated with shorter overall survival. The 
prognostic value of SLPI was independent of established clin-
ical risk factors that were previously associated with poorer 
overall survival in this cohort.26 Therefore, our findings indi-
cate that assessment of SLPI expression could help to predict 
the prognosis of patients with CRC after resection of liver 
metastases. Subsequent mechanistic analyses are required to 
investigate whether SLPI plays a causal role in CRC and may 
reveal previously unknown mechanisms involved in 
metastasis.
In the healthy intestine, SLPI prevents tissue damage by 
inhibiting neutrophil proteases and exerting antimicrobial 
activity and suppresses infiltration of immune cells to maintain 
intestinal homeostasis.8,37 Therefore, in CRC, SLPI may pre-
dominantly act on the tumor microenvironment, rather than 
on tumor cell proliferation itself. Most proteins known to 
mediate immune evasion in CRC, including programmed 
death ligand 1 (PD-L1) and CEA, act by suppressing T cell or 
NK cell activation in the tumor niche.9,10 Although the exact 
functional role of SLPI in CRC remains to be determined, it is 
likely that the pleiotropic functions of SLPI promote immune 
evasion via multiple processes. Firstly, as it directly suppresses 
the production of chemokines by intestinal epithelial cells 
under homeostasis, SLPI may also directly suppress chemokine 
gradients and thus prevent recruitment of immune cells to the 
tumor niche. This effect may be clinically relevant, as the 
absence of tumor-infiltrating lymphocytes in both primary 
CRC38 and CRCLM39 is associated with shorter overall survi-
val. Secondly, soluble SLPI can exert generalized immune sup-
pression by acting as an NF-κB inhibitor.40,41 Lastly, the 
function of SLPI as a protease inhibitor may provide tumor 
cells with the capacity to defend their niche by inhibiting the 
protease activity of infiltrating immune cells .4 Moreover, mul-
tiple functions of SLPI may promote tumor metastasis. In 
particular, SLPI enhanced the formation of vessel-like struc-
tures and increased the metastatic potential of tumor cells in 
a mouse model of polyclonal mammary carcinoma.16 The 
anticoagulative activity of SLPI partly explained the ability of 
SLPI to drive metastasis in this model.16 Given its diverse 
activities, SLPI is likely to exert a number of functions in 
various processes related to tumor growth and metastasis. 
Future studies are required to elucidate the precise role of 
SLPI in processes related to the progression and metastasis of 
CRC, including immune modulation.
Other proteins with significant prognostic value in this 
cohort are aurora kinase A (AURKA), epidermal growth factor 
receptor (EGFR), prostaglandin-endoperoxide synthase 2 
(PTGS2, also known as cyclooxygenase-2), glucose transporter 
1 (SLC2A1) and vascular endothelial growth factor A (VEGFA) 
.26,42,43 This study demonstrates SLPI expression has similar 
prognostic value in patients with CRCLM as these proteins. 
However, SLPI is likely to have a different biological function 
in CRC compared to these other prognostic proteins. In short, 
both AURKA and EGFR promote sustained proliferation of 
tumor cells, SLC2A1 expression is related to anaerobic glyco-
lysis, VEGFA promotes angiogenesis and contributes to induc-
tion of regulatory T cells44 and PTGS2 is involved in both the 
proliferation and invasion of tumor cells. In addition, PTGS2- 
derived prostaglandin E2 acts on the tumor niche as it pro-
motes activation of myeloid-derived suppressor cells, and 
thereby inhibits cytotoxic T cell and NK cell activation.45 We 
hypothesize that SLPI prevents the recruitment of immune 
cells to the tumor, in contrast to VEGFA and PTGS2 which 
suppress the activation of T cells or NK cells in the tumor 
niche.
SLPI protein expression in both the primary CRC tissues and 
liver metastases varied substantially between patients. However, 
SLPI was invariably localized to the cytoplasm, mainly on the 
luminal side of the tumor cells, which is similar to the expression 
pattern observed in healthy intestinal epithelial cells .37 The 
factors that trigger SLPI expression in some tumors, but not in 
others, remain unclear. We observed SLPI was strongly expressed 
in a subgroup of primary CRC tumors, and in these cases, high 
SLPI expression in the primary tumor was positively associated 
8 S. NUGTEREN ET AL.
with high SLPI expression in the matched CRCLM, which indi-
cates that SLPI may already be upregulated in non-metastatic 
tumor cells. Interestingly, SLPI was expressed at relatively higher 
levels in primary tumors than in the corresponding liver metas-
tases, indicating that SLPI may be downregulated during the 
progression to metastasis, possibly due to the influence of the 
local environment in the liver. High SLPI expression in primary 
CRC was also associated with shorter overall survival after resec-
tion of the liver metastases, suggesting that assessment of SLPI 
expression in primary CRC samples holds prognostic value for 
patients for whom resected liver metastases are not available.
We used two antibodies to detect SLPI expression, one 
monoclonal and one polyclonal. We observed the same result 
using both antibodies: high SLPI expression in CRCLM and 
high SLPI expression in primary tumors were associated with 
shorter overall survival after resection of liver metastases in 
patients with CRCLM. Overall, the monoclonal antibody led to 
lower SLPI expression scores than the polyclonal antibody, 
which could be explained by the fact that monoclonal antibo-
dies only recognize one epitope, in contrast to polyclonal anti-
bodies. Indeed, we found that the monoclonal antibody was 
better at discriminating patients with a poorer prognosis, as the 
association between SLPI expression and overall survival was 
only significant for the monoclonal antibody. However, the 
similar results obtained using the monoclonal and polyclonal 
antibody strengthen our argument that SLPI protein expres-
sion is related to prognosis in CRCLM patients.
In conclusion, high SLPI expression in both CRCLM and 
primary CRC are associated with a poorer prognosis after 
resection of liver metastases. Further elucidation of the invol-
vement of SLPI in various tumor-promoting processes may 
help to identify new targets for cancer therapy. In view of the 
role of SLPI in intestinal homeostasis, we suggest that SLPI 
influences the anti-tumor immune response in CRC.
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